Prospective studies are needed to elucidate the clinical presentation, evolution and outcome of such patients. Pub Med Rheumatology. 2013 Mar;52(3):560-7. (Also see: What is Scleroderma?, Antibodies in Systemic Scleroderma, Raynaud's)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.